Efficacy and prognostic analysis of pyrotinib combined with THP regimen in the treatment of advanced HER-2 positive breast cancer
Objective To investigate the efficacy and prognosis of pyrotinib combined with THP regimen in the treatment of advanced HER-2 positive breast cancer patients.Methods A total of 121 patients with advanced HER-2 positive breast cancer who were admitted to Cangzhou Central Hospital from June 2019 to November 2020 were collected and divided into a control group(n=61)and an ob-servation group(n=60)based on different treatment regimens.Both groups were treated with the THP regimen,while the observation group received pyrotinib treatment on this basis.The treatment cycle was 21 days,and both groups were treated for 4 cycles.The objective response rate(ORR)and disease control rate(DCR),progression-free survival(PFS),and overall survival(OS)were observed in both groups.The levels of tumor markers(VEGF,CEA,CA153,CA125),T lymphocyte subsets,and the occurrence of adverse reactions were compared before and after treatment.Results After treat-ment,the ORR in the observation group was higher than that in the control group(85.00％vs.68.85％,P＜0.05),and the PFS was prolonged(15.80 months vs.9.70 months,t=-5.142,P＜0.01).There was no significant difference in DCR between the two groups(P＞0.05).The levels of tumor markers VEGF,CEA,CA153,and CA125 in the observation group decreased more significant-ly than those in the control group(P＜0.05).The CD4+T cell decreased significantly,and the CD8+T cell increased significantly in both groups,with statistically significant differences compared with before treatment(P＜0.001),and the changes in the control group were more pronounced.There was no statistical difference in the occurrence of adverse reactions between the two groups(P＞0.05).Conclusion Pyrotinib combined with THP regimen has good clinical efficacy and prognosis in the treatment of patients with advanced HER-2 positive breast cancer,which can improve the biological behavior of tumor cells without increasing adverse reactions,indicating good safety.
万方数据
维普
